Navigation Links
AcelRx Pharmaceuticals to Hold Second Quarter Financial Results Conference Call and Webcast on Monday, August 11th, 2014.
Date:8/7/2014

s for Zalviso, and has submitted an NDA to the FDA seeking approval for Zalviso in the treatment of moderate-to-severe acute pain in adult patients in the hospital setting and on July 25th, received a Complete Response Letter from the FDA.  AcelRx plans to initiate a Phase 3 clinical trial for ARX-04, a product candidate for the treatment of moderate-to-severe acute pain in a medically supervised setting, by the end of 2014. The Company has two additional pain treatment product candidates, ARX-02 and ARX-03, which have completed Phase 2 clinical development.  For additional information about AcelRx's clinical programs, please visit www.acelrx.com.

Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements related to the Company's Zalviso NDA and the Complete Response Letter ("CRL"), our plans to address the issues raised in the CRL, our anticipated resubmission of the Zalviso NDA to the FDA, including the scope of the resubmission and the timing of the resubmission and FDA review time, planned initiation of the Phase 3 clinical trial for ARX-04, and the therapeutic potential of AcelRx Pharmaceuticals' product candidates, including Zalviso. These forward-looking statements are based on AcelRx Pharmaceuticals' current expectations and inherently involve significant risks and uncertainties. AcelRx Pharmaceuticals' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to: AcelRx Pharmaceuticals' ability to receive regulatory approval for Zalviso; any delays or inability to obtain and maintain regulatory approval of its product candidates, including Zalviso, in the United States and Europe; AcelRx's ability to build an effective comme
'/>"/>

SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. AcelRx Pharmaceuticals Confirms July 27, 2014 PDUFA Date for Zalviso
2. AcelRx Secures $40 Million Credit Facility with Hercules Technology Growth Capital
3. AcelRx Pharmaceuticals Presents ARX-04 Dose-Finding Phase 2 Study Data at Anesthesia Medical Conference
4. AcelRx Pharmaceuticals Adds New Board Member
5. Annual General Meeting Schedules, New Drug Applications, Positive Study Results, Conference Participations, and Secondary Offerings - Research Report on Mindray, AcelRx, Merrimack, ZELTIQ, and Clovis
6. AcelRx Pharmaceuticals to Present at the 25th Annual Piper Jaffray Healthcare Conference
7. AcelRx Pharmaceuticals Reports Third Quarter 2013 Financial Results
8. AcelRx Pharmaceuticals to Hold Third Quarter 2013 Financial Results Conference Call and Webcast on November 5, 2013
9. David H. Chung Joins AcelRx Pharmaceuticals as Chief Commercial Officer
10. AcelRx Pharmaceuticals to Present at the Stifel Healthcare Conference 2013
11. AcelRx Pharmaceuticals Reports Second Quarter 2013 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... PUNE, India , September 4, 2015 /PRNewswire/ ... Industry, 2015 Market Research Report is a professional ... the global Surgical Gown industry with a focus ... will take 2-3 working days once an order ... gown market spread across 150 pages, analyzing and ...
(Date:9/4/2015)... 4, 2015 According to a ... Plateletpheresis, Erythrocytapheresis, Leukapheresis, and Photopheresis) by Procedure (Therapeutic Apheresis, ... - Global Forecast to 2020", published by MarketsandMarkets, the ... Billion by 2020, growing at a CAGR of 11.2% ... Browse 139 Tables and 45 F ...
(Date:9/4/2015)...  Cumberland Pharmaceuticals (CPIX), today announced that A.J. Kazimi ... on September 10, 2015. DATE: Thursday, September ... http://tinyurl.com/sep10pre This will be a ... ask the company questions in real-time - both in ... trade booth." If attendees are not able to join ...
Breaking Medicine Technology:Surgical Gown Market 2020 Forecasts With a Focus on China 2Surgical Gown Market 2020 Forecasts With a Focus on China 3Surgical Gown Market 2020 Forecasts With a Focus on China 4Apheresis Market Worth 2.5 Billion USD by 2020 2Apheresis Market Worth 2.5 Billion USD by 2020 3Apheresis Market Worth 2.5 Billion USD by 2020 4Apheresis Market Worth 2.5 Billion USD by 2020 5Cumberland Pharmaceuticals to Webcast, Live, at VirtualInvestorConferences.com September 10 2
... - Phase 2 trial expected to begin in late ... June 4 Nuvelo, Inc.,(Nasdaq: NUVO ) today ... a,single-center, Phase 1b trial to determine the safety, tolerability ... direct,thrombin-inhibiting aptamer, in approximately 30 healthy male volunteers., ...
... at American Society of Clinical Oncology meeting indicate ... compared to historical data., PRINCETON, N.J., June ... CPX-1 Phase 2 clinical trial in patients,with advanced ... and floxuridine, based on the company,s proprietary,CombiPlex(TM) technology. ...
Cached Medicine Technology:Nuvelo Initiates Phase 1B Clinical Trial of Anticoagulant NU172 2Nuvelo Initiates Phase 1B Clinical Trial of Anticoagulant NU172 3Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer 2Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer 3
(Date:9/4/2015)... ... September 04, 2015 , ... Keeping mold top of mind is important ... quite common. Mold can grow anywhere - on carpet, clothing, food, paper, and even ... moisture and water in the home is key to preventing mold growth, which if ...
(Date:9/4/2015)... ... September 04, 2015 , ... Bio-Logic Aqua® Research, a ... announced its only mission and research focus: Water Life Science®. In the current ... water evaporation is becoming dangerously accelerated. As a result of the global fresh ...
(Date:9/4/2015)... New York, NY (PRWEB) , ... September 04, 2015 , ... ... 400 meters qualifying heat, and followed up with victory in the men’s 400 meters ... Caribbean (NACAC) Senior Track and Field Championships in San Jose, Costa Rica in August ...
(Date:9/4/2015)... ... 04, 2015 , ... EMED Jamaica Global Ltd. (EMED), Jamaica’s ... entered into a multi-year agreement with Health City Cayman Islands. , ( http://www.healthcitycaymanislands.com ... American healthcare, Jamaican healthcare and Health City Cayman Islands to deliver high-quality, affordable ...
(Date:9/3/2015)... ... , ... TransPack Toon gives users a set of 90 cartoon transitions for ... in 30 different styles. Presets range from snow, underwater, forest, futuristic, city and many ... features 90 cartoon transitions from 30 unique styles. Editors can choose between line ...
Breaking Medicine News(10 mins):Health News:September is Mold Awareness Month 2Health News:September is Mold Awareness Month 3Health News:September is Mold Awareness Month 4Health News:Bio-Logic Aqua® Research Announces Water Life Science and Body Water Evaporation as Research Focus and Mission 2Health News:Bio-Logic Aqua® Research Announces Water Life Science and Body Water Evaporation as Research Focus and Mission 3Health News:Lalonde Gordon’s Recipe Brings Home the Gold 2Health News:Lalonde Gordon’s Recipe Brings Home the Gold 3Health News:EMED Agreement with Health City Cayman Islands Provides for Up to 80% Savings for Patients in Need of Medical Procedures 2Health News:EMED Agreement with Health City Cayman Islands Provides for Up to 80% Savings for Patients in Need of Medical Procedures 3Health News:EMED Agreement with Health City Cayman Islands Provides for Up to 80% Savings for Patients in Need of Medical Procedures 4Health News:EMED Agreement with Health City Cayman Islands Provides for Up to 80% Savings for Patients in Need of Medical Procedures 5Health News:EMED Agreement with Health City Cayman Islands Provides for Up to 80% Savings for Patients in Need of Medical Procedures 6Health News:Pixel Film Studios Releases TransPack Toon, a New FCPX Transition 2
... Shelves for Father,s Day , , NEW YORK, June 8 ... pain may lie in a $59.99 biomechanically-engineered foam and rubber flip-flop ... for the sixty million adults who reported persistent back pain last ... be a medical breakthrough is now available in the Dass, a ...
... , BALTIMORE, June 8 Metastorm, a leading provider ... and Enterprise Architecture (EA) software for aligning strategy with ... customer Wyeth Pharmaceuticals as one of this year,s CIO ... Wyeth is one of the world,s largest pharmaceutical and ...
... Factor Driving the Market Decline Will be Singulair,s Loss ... Decision Resources , , WALTHAM, Mass., June 8 ... and advisory firms for pharmaceutical and healthcare issues, finds ... and cost consciousness will reduce the asthma drug market ...
... Cedars-Sinai Outpatient Cancer Center Appointed COO , , ... today announced the appointment of Paul R. O,Dea to ... formerly Vice President, Aptium Oncology and Executive Director, Cedars-Sinai ... hospital-based cancer centers. The appointment was effective June 1, ...
... LOMBARD, Ill., June 8 A major session at the ... Conference will focus on how supply chains are helping to ... will be held September 20-23 in Chicago, Illinois. , ... improving delivery of drugs, vaccines, and other remedies to needy ...
... More Efficient Operation for Gateway Healthcare , , ... announced today that it is addressing the ... with the unique, next generation voice product, Cox ... moved its telecommunications services from a competitive provider to ...
Cached Medicine News:Health News:One of Women's Best Kept Secrets is Now Available in the Men's Department 2Health News:Metastorm Customer, Wyeth Pharmaceuticals, Wins CIO 100 Award for BPM Project 2Health News:Generic Erosion, Increased Competition and Cost Consciousness Will Reduce Overall Asthma Drug Market by $1.8 Billion from 2008 to 2018 2Health News:Aptium Oncology Names New Chief Operating Officer 2Health News:Cox Business Addresses Complex Voice Needs of Health Care Organization 2Health News:Cox Business Addresses Complex Voice Needs of Health Care Organization 3Health News:Cox Business Addresses Complex Voice Needs of Health Care Organization 4
... a unique and versatile posterior spinal implant ... as a translational implant in correction of ... for bone or metallic implants, cables have ... configurations. Songer Cables offer advantages in strength, ...
Demineralized bone matrix dispensed in a jar. Fibers will be free of foreign matter. Glycerol 70-88% by weight. Calcium content less than 8%....
Demineralized bone matrix dispensed in a syringe. DBM will be free of foreign matter. Demineralized bone matrix particle size 125 to 850 . Glycerol 70-88% by weight. Calcium content less than 8%....
... matrix and conductive cancellous chips. ... be free of foreign matter. ... is 125 to 1000 . ... 1 - 8 mm. 5:3 ...
Medicine Products: